Fraxinellone (oral gavage; 30 and 100 mg/kg; every three days; 30 days) significantly suppresses tumor growth, reduces HIF-1α, pTyr705 STAT3, PD-L1 and VEGF staining compared with the control group in female athymic BALB/c nude mice.
Animal Model:
BALB/c nude mice
Dosage:
30 and 100 mg/kg
Administration:
Oral gavage; 30 and 100 mg/kg; every three days; 30 days
Result:
Significantly suppressed tumor growth.